Fig. 2: Summary of clinicopathological characteristics and ctDNA/CTCs detection using ddPCR and PSS technologies.
From: Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients
The plot summarizes the presence/absence of ctDNA/CTCs and provides information on the inferred mutant genomic equivalents (MGE). The change in detection between pre- and post-neoadjuvant chemotherapy (NAC) plasma samples is indicated. Axillary lymph node status is categorized as follows: N0 (not affected), N1 (1–3 affected nodes), N2 (4–9 affected nodes), and N3 (10 affected nodes). The table also includes PCR results in surgical tissue and the relapse status. PCR pathological complete response, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, NAC neoadjuvant chemotherapy, PSS Plasma SeqSenseiTM, ER estrogenic receptor, PR progesterone receptor, ctDNA circulating tumor DNA, CTCs circulating tumor cells, MGE mutant genomic equivalents.
